Massachusetts Financial Services Co. MA Has $13.54 Million Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Massachusetts Financial Services Co. MA cut its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 7.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 459,045 shares of the company’s stock after selling 39,176 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Immunocore were worth $13,542,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in IMCR. China Universal Asset Management Co. Ltd. lifted its stake in shares of Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after acquiring an additional 960 shares during the period. NEOS Investment Management LLC raised its holdings in Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after purchasing an additional 1,102 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Immunocore by 72.9% in the 3rd quarter. XTX Topco Ltd now owns 15,459 shares of the company’s stock worth $481,000 after purchasing an additional 6,516 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Immunocore during the third quarter worth $739,000. Finally, Assetmark Inc. raised its stake in Immunocore by 5.3% during the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock worth $949,000 after buying an additional 1,616 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

Shares of IMCR stock opened at $26.28 on Tuesday. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The firm has a fifty day simple moving average of $29.68 and a two-hundred day simple moving average of $30.72. Immunocore Holdings plc has a 12 month low of $24.84 and a 12 month high of $63.94. The firm has a market capitalization of $1.31 billion, a PE ratio of -27.66 and a beta of 0.75.

Insider Activity

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the acquisition, the director now owns 2,144,060 shares of the company’s stock, valued at $63,721,463.20. This represents a 60.40 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on IMCR shares. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. Mizuho lowered their target price on Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a report on Monday. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Immunocore has a consensus rating of “Moderate Buy” and an average price target of $65.18.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.